ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF

• Main Authors: ROSELYNE CASTONGUAY, PEARSALL ROBERT SCOTT, SAKO DIANNE S, YOSSI DAGON, KNOPF JOHN, RAVINDRA KUMAR, LI GANG, GRINBERG ASYA
• Format: Patent
• Language: English; Japanese
• Published: 26.07.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide ALK7:ActRIIB heteromultimers and uses thereof.SOLUTION: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB. In certain aspects, the ALK7:ActRIIB heteromultimers can be used to improve metabolic parameters in patients in need thereof. In certain aspects, the ALK7:ActRIIB heteromultimers can be used to treat or prevent one or more kidney-related diseases or disorders in patients in need thereof.SELECTED DRAWING: None 【課題】ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用。【解決手段】ある特定の態様では、本開示は、ＡＬＫ７受容体の細胞外ドメインと、ＡｃｔＲＩＩＢの細胞外ドメインとを含む、可溶性のへテロマーポリペプチド複合体を提供する。ある特定の態様では、これらのＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体を使用して、それを必要とする患者における代謝パラメーターを改善することができる。ある特定の態様では、これらのＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体を使用して、それを必要とする患者における１つまたは複数の腎臓関連疾患または障害を処置または予防することができる。【選択図】なし